Biologic Behavior and Clinical Outcome of 25 Dogs with Canine Appendicular Chondrosarcoma Treated by Amputation: A Veterinary Society of Surgical Oncology Retrospective Study

Farese, James P.; Kirpensteijn, Jolle; Kik, Marja; Bacon, Nicholas J.; Waltman, Suzanne Shelly; Séguin, Bernard; Kent, Michael S.; Liptak, Julius M.; Straw, Rodney C.; Chang, Myron; Jiang, Yupeng; Withrow, Stephen J.

doi:10.1111/j.1532-950x.2009.00606.x

Cited by 46 publications

(41 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Any tumour causing pain, affecting normal function or which is ulcerated/bleeding can be treated with palliative surgery. Examples include soft tissue sarcomas or mast cell tumours in locations where margins are not achievable or curative intent surgery has been declined, and oral tumours such as melanoma (Verstraete 2005, Waltman and others 2007, Kramer and others 2008, Liptak and others 2008a, b, Morello and others 2008, Stefanello and others 2008, Stratmann and others 2008, Borrego and others 2009, Farese and others 2009, Mayer and others 2009, Arzi and Verstraete 2010, Nelissen and White 2012, Tuohy and others 2012, 2014, Bray and others 2014, Cameron and others 2015, Garneau and others 2015, Matz 2015, Wendelburg and others 2015) (Figs 1 to 3). Thorascopic procedures may allow for faster postoperative recovery (Mayhew and Friedberg 2008, Peláez and others 2008, Naan and others 2013, Ployart and others 2013, Shaver and others 2015).…”

Section: Surgerymentioning

confidence: 99%

Palliative care in small animal oncology

Mason¹

2016

In Practice

View full text Add to dashboard Cite

Cancer is a common diagnosis in companion animals and, increasingly, clients choose to pursue treatment for their pets. Veterinary oncology is a rapidly growing field and diagnostic and treatment options for animals with cancer are constantly improving and becoming more widely available. Treatment outcomes can be good, but in many cases definitive treatment is not an option and palliative treatment is necessary. This article explores the palliative care of dogs and cats that have been diagnosed with cancer and summarises the various treatment options, with a particular focus on quality of life and the role of communication in the decision-making process.

show abstract

Section: Surgerymentioning

confidence: 99%

Palliative care in small animal oncology

Mason¹

2016

In Practice

View full text Add to dashboard Cite

show abstract

“…The dog developed a harsh cough and became anorectic 15 weeks after surgery; thoracic radiography revealed changes compatible with pulmonary metastasis and the patient was euthanatised (Flanders and others ). However, more recent studies have reported good overall median survival time of dogs treated for skeletal and extraskeletal CSA(Pirkey‐Ehrhart and others , Dernell and others , Waltman and others , Liptak and others , Farese and others ). Survival was significantly associated with tumour grade, with dogs with tumour grade of 1, 2 and 3 having median survival time of 6, 2·7 and 0·9 years, respectively (Farese and others ).…”

Section: Discussionmentioning

confidence: 99%

“…However, more recent studies have reported good overall median survival time of dogs treated for skeletal and extraskeletal CSA(Pirkey‐Ehrhart and others , Dernell and others , Waltman and others , Liptak and others , Farese and others ). Survival was significantly associated with tumour grade, with dogs with tumour grade of 1, 2 and 3 having median survival time of 6, 2·7 and 0·9 years, respectively (Farese and others ). Wide surgical excision significantly improves survival time for dogs with CSA of non‐nasal bony sites, but does not affect the likelihood of metastasis.…”

Section: Discussionmentioning

confidence: 99%

Successful management of an arytenoid chondrosarcoma in a dog

Muraro¹,

Aprea²,

White³

2012

J of Small Animal Practice

View full text Add to dashboard Cite

An eight-year-old Doberman pinscher was presented with a four-week history of inspiratory stridor, dysphonia, inappetence and weight loss. Inspiratory stridor was apparent and became more pronounced during gentle compression of the larynx. Previous investigations, including laryngoscopy, had revealed the presence of a left-sided arytenoid mass. Histological examination of pinch biopsies was not diagnostic. The mass was removed by resection of the arytenoid cartilage through a ventral laryngotomy allowing salvage of the cuneiform process. Histological examination of the laryngeal mass was consistent with a chondrosarcoma, grade I, infiltrating the arytenoid cartilage. Re-examination at 12 months showed complete resolution of the clinical signs and no signs of metastatic disease. To the authors' knowledge this is the first report of successful surgical intervention for laryngeal chondrosarcoma. This case demonstrates that resection via a ventral laryngotomy may be a viable and curative therapeutic option for some sarcomas of the larynx.

show abstract

“…Considering the high similarity at the clinical, histopathological and molecular levels, spontaneous tumours in dogs are considered excellent models for human diseases, representing an alternative to rodents for studying cancer biology and therapy . Canine osteosarcoma (OSA) represents the most common primary malignant bone tumour in dogs, accounting for more than 80% of all bone tumours; it is locally aggressive and is characterized by a high metastatic potential and poor prognosis . Furthermore, the role of several tyrosine kinase receptors (TKRs) in the pathogenesis of canine OSA was recently demonstrated, which reveals the utility of tyrosine kinase inhibitors (TKIs) against specific targets …”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models

Sánchez-Céspedes

Accornero

Miretti

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Canine osteosarcoma (OSA) is the most common primary malignant bone tumour in dogs, and it has a high metastatic rate and poor prognosis. Toceranib phosphate (TOC; Palladia, Zoetis) is a veterinary tyrosine kinase inhibitor that selectively inhibits VEGFR‐2, PDGFRs and c‐Kit, but its efficacy is not yet fully understood in the treatment of canine OSA. Here, we evaluated the functional effects of TOC on six OSA cell lines by transwell, wound healing and colony formation assays. Subsequently, two cell lines (Wall and Penny) were selected and were inoculated in mice by intrafemoral injection to develop an orthotopic xenograft model of canine OSA. For each cell line, 30 mice were xenografted; half of them were used as controls, and the other half were treated with TOC at 40 mg/kg body weight for 20 days. TOC inhibited cell growth of all cell lines, but reduced invasion and migration was only observed in Penny and Wall cell lines. In mice engrafted with Penny cells and subjected to TOC treatment, decreased tumour growth was observed, and PDGFRs and c‐Kit mRNA were downregulated. Immunohistochemical analyses demonstrated a significant reduction of Ki67 staining in treated mice when compared to controls. The results obtained here demonstrate that TOC is able to slightly inhibit cell growth in vitro, while its effect is evident only in a Penny cell xenograft model, in which TOC significantly reduced tumour size and the Ki67 index without modifying apoptosis markers.

show abstract

Biologic Behavior and Clinical Outcome of 25 Dogs with Canine Appendicular Chondrosarcoma Treated by Amputation: A Veterinary Society of Surgical Oncology Retrospective Study

Abstract: The overall prognosis for appendicular chondrosarcoma is better than that of appendicular osteosarcoma treated by amputation alone or in combination with chemotherapy.

Cited by 46 publications

References 5 publications

Palliative care in small animal oncology

Palliative care in small animal oncology

Successful management of an arytenoid chondrosarcoma in a dog

In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models

Contact Info

Product

Resources

About